Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma ownership update: Capital International Investors reports beneficial ownership of 2,013,285 shares, representing 3.2% of common stock. The filing states 61,977,408 shares believed outstanding and shows sole voting power of 2,005,343 and sole dispositive power of 2,013,285.
Ascendis Pharma A/S granted new equity incentives to employees. On May 12, 2026, the board approved 31,250 warrants for certain employees under Appendix 1a of the Articles of Association. Each warrant allows purchase of one ordinary share at an exercise price of US $237.65, the closing share price on the grant date.
Twenty‑five percent of the warrants vest one year after grant, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and potential earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,580,593 shares remain available for future grants under the Articles of Association.
Ascendis Pharma A/S officer Flemming Steen Jensen sold all his reported holdings in a single transaction. On May 11, 2026, he executed an open-market sale of 19,460 Ordinary Shares at an average price of $238.4903 per share, leaving 0 shares directly owned after the trade.
Ascendis Pharma A/S filed a Form 144 reporting a proposed sale of 19,460 ordinary shares on 05/11/2026 through Citigroup Global Markets. The filing shows an aggregate value of $4,641,021.92 and lists the seller as a Share Plan Account tied to Ascendis Pharma A/S; the method is labeled Compensation.
The excerpt also records a prior sale of 10,277 shares on 03/02/2026 with an aggregate amount of $2,407,985.38 in the past three months.
Ascendis Pharma A/S - ADR amended a Schedule 13G/A to report that T. Rowe Price Investment Management, Inc. beneficially owns 6,506,219 shares of ADRs, representing 10.5% of the class. The filing lists 6,193,667 shares with sole voting power and 6,501,324 shares with sole dispositive power. The amendment is signed by Ellen York on 05/07/2026.
Ascendis Pharma A/S ownership disclosure: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,162,042 ADRs, equal to 9.9% of the class as reported 03/31/2026. The filing lists sole voting power for 5,884,715 shares and sole dispositive power for 6,162,042 shares.
Ascendis Pharma A/S reported a sharp turnaround in first quarter 2026 results, led by strong growth in key endocrine products. Total revenue rose to €246.6 million from €101.0 million a year earlier, driven mainly by YORVIPATH® revenue of €196.9 million versus €44.7 million and SKYTROFA® revenue of €44.0 million.
Research and development expenses fell to €59 million from €87 million, reflecting completed trials and a reversal of prior YUVIWEL® inventory write-downs, while selling, general, and administrative costs increased to €145 million due to commercial expansion and global launch activities. Operating profit reached €24.8 million, compared to an operating loss of €104.2 million in 2025.
Net profit was €629.3 million, or €9.75 diluted earnings per share, versus a €94.6 million loss, largely because Ascendis recognized €679 million of previously unrecognized deferred tax assets. On a non-IFRS basis, operating profit was €55.2 million and net profit was €17.6 million, indicating underlying profitability. Cash and cash equivalents totaled €572.8 million as of March 31, 2026. The company also entered an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $187.5 million and highlighted strong early YUVIWEL® and YORVIPATH® patient uptake.
Ascendis Pharma reported a sharp turnaround in Q1 2026, posting net profit of €629.3 million versus a €94.6 million loss a year earlier. Revenue more than doubled to €246.6 million, driven mainly by YORVIPATH (€196.9 million) and SKYTROFA (€44.0 million) commercial sales.
Results were boosted by recognition of €679.6 million of previously unrecognized deferred tax assets, lifting equity to €488.0 million from a negative position. Cash and cash equivalents were €572.8 million, while total financial liabilities were €1.28 billion, including €448.2 million of convertible notes and €298.1 million of capped royalty funding liabilities.
During the quarter Ascendis repurchased 254,027 shares for $60.0 million under a $120 million buyback and reversed €10.9 million of prior inventory write-downs after FDA approval of YUVIWEL for achondroplasia. Subsequent events include full conversion of $575 million of 2.25% convertible notes into 3,635,813 shares and an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $187.5 million.
Ascendis Pharma A/S files Amendment No. 12 to a Schedule 13G/A reporting beneficial ownership of 3,852,100.98 shares, representing 6.6% of common stock held by FMR LLC. The filing lists Abigail P. Johnson as having dispositive power over the same 3,852,100.98 shares.
The schedule notes the filing entity is FMR LLC (245 Summer Street, Boston) and references an attached Exhibit 99 and a Power of Attorney effective April 13, 2026.
Ascendis Pharma A/S is redeeming all $575.0 million of its 2.25% Convertible Senior Notes due 2028 on May 6, 2026. Noteholders will receive cash equal to 100% of principal plus accrued interest, or can choose to convert into ordinary shares before the redemption.
As of April 21, 2026, each $1,000 principal amount is redeemable for about $1,002.19, or convertible into 6.0118 shares, implying a conversion price of roughly $166.34 per share. During a special make-whole period, the conversion rate temporarily increases to 6.3232 shares, lowering the effective conversion price to about $158.15 per share and potentially increasing dilution.